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NRK1 controls nicotinamide mononucleotide and
nicotinamide riboside metabolism in mammalian
cells
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Yanes5,8,9, Charles Brenner3 & Carles Canto´1,2
NADþ is a vital redox cofactor and a substrate required for activity of various
enzyme families, including sirtuins and poly(ADP-ribose) polymerases. Supplementation with
NADþ precursors, such as nicotinamide mononucleotide (NMN) or nicotinamide riboside
(NR), protects against metabolic disease, neurodegenerative disorders and age-related
physiological decline in mammals. Here we show that nicotinamide riboside kinase 1 (NRK1)
is necessary and rate-limiting for the use of exogenous NR and NMN for NADþ synthesis.
Using genetic gain- and loss-of-function models, we further demonstrate that the role of
NRK1 in driving NADþ synthesis from other NADþ precursors, such as nicotinamide
or nicotinic acid, is dispensable. Using stable isotope-labelled compounds, we conﬁrm NMN
is metabolized extracellularly to NR that is then taken up by the cell and converted into
NADþ . Our results indicate that mammalian cells require conversion of extracellular NMN to
NR for cellular uptake and NADþ synthesis, explaining the overlapping metabolic effects
observed with the two compounds.
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N
icotinamide adenine dinucleotide (NADþ ) is an essential
cofactor for multiple cellular redox processes linked
to fuel utilization and energy metabolism, including
the mitochondrial oxidative phosphorylation system1,2. NADþ
is also a substrate for multiple enzymes, including sirtuins
and poly(ADP-ribose) polymerases (PARPs), which hydrolyse
the glycosidic bond between the nicotinamide (NAM) and
ADP-ribosyl moieties of NADþ (ref. 3). In the case of sirtuins,
this reaction is coupled to protein deacylation, which yields
the deacylated protein plus NAM and a mixture of 20- and
30-O-acyl-ADPribose as products. On the basis of the high Km for
NADþ of some sirtuins, these enzymes have been postulated to
act as NADþ sensors, translating metabolic cues into enzymatic
and transcriptional adaptations3. Importantly, sirtuin activation
has been associated with an improvement in metabolic efﬁciency
and healthspan in mammals4,5.
The relevance of NADþ precursors in health is further
illustrated by the historical use of nicotinic acid (NA) and NAM,
commonly known as niacin or vitamin B3, in prevention
and treatments for pellagra and dyslipidemia6. A limitation in
the pharmacological use of niacin against dyslipidemia is
the occurrence of unpleasant side effects in the form of
ﬂushing, mostly due to activation of the GPR109A receptor by
NA7. NAM is much less efﬁcient than NA as a lipid lowering
agent, likely because NAM exerts product inhibition on
sirtuin activity1. The metabolism of these conventional niacin
compounds to NADþ is also different, as NA is converted via the
three-step Preiss–Handler pathway, whereas NAM is metabolized
into nicotinamide mononucleotide (NMN) via nicotinamide
phosphoribosyltransferase (NAMPT) and then by NMN
adenylyltransferases (NMNAT1-3) into NADþ (ref. 8).
As a phosphorylated compound, NMN is not a vitamin
precursor of NADþ but rather a biosynthetic intermediate2.
However, administration of NMN to mice produces multiple
beneﬁcial effects. It improves insulin sensitivity in high-fat
diet-induced diabetes9, protects the heart from ischaemia-
reperfusion injury10 and restores mitochondrial function in
aged muscles11,12. Though the phosphoribosyl pyrophosphate
substrate of NAMPT has not been detected extracellularly13,
it has been speculated that NMN might be a circulating NADþ
precursor, produced by a circulating extracellular NAMPT
activity14. However, there are discordant reports on circulating
NMN concentrations, which have been reported to be o50 nM
by LC-tandem mass spectrometry13 to 480 mM (ref. 14).
The mechanisms by which extracellular NMN is converted to
cellular NADþ also remain elusive. On the one hand, it was
claimed that NMN is transported intact to hepatocytes9. On the
other hand, it has been proposed that extracellular
dephosphorylation of NMN to nicotinamide riboside (NR) is
required to elevate cellular NADþ metabolism1,15–17.
NR is a recently described NADþ precursor that might
overcome the problems linked to the administration of higher
doses of NA and NAM18. NR boosts NADþ synthesis and sirtuin
activation without affecting GPR109A19. NR supplementation
increases lifespan in yeast, Caenorhabditis elegans and mice20–22
and improves high-fat diet-induced metabolic complications in
mice19,23. NR has recently been shown to be the favoured orally
available hepatic precursor to NADþ in mice and to safely boost
human NADþ metabolism in single oral doses24.
NR naturally occurs in milk18,25 and its conversion to
NADþ is initiated by phosphorylation of NR to NMN by NR
kinases (NRKs)18. NRKs, encoded by the Nmrk genes, are highly
conserved enzymes in all eukaryotes18. In mammals there are two
NRK enzymes, NRK1 and NRK2, but little is known about their
physiological roles. In this study, we explore how modulation of
NRK activity inﬂuences the action of NADþ precursors. For this
purpose, we created NRK gain- and loss-of function cellular
models as well as an Nmrk1-deﬁcient mouse model (NRK1KO).
Our results indicate that NRKs are rate-limiting for NR
metabolism in mammalian cells, and also a required enzymatic
activity for conversion of exogenously administered NMN to
NADþ .
Results
NRKs are rate-limiting for NR/NMN-driven NADþ synthesis.
We took advantage of the low endogenous NRK1 and NRK2
levels in NIH/3T3 cells (Fig. 1a,b) to test how increased NRK
expression would affect NR-driven NADþ production
in mammalian cells. For this purpose, we generated constructs
to overexpress murine NRK1 or NRK2 enzymes, alongside
predicted catalytically inactive NRK1-D36A, NRK1-E98A,
NRK2-D35A and NRK2-D100A mutants26. NRK1 and NRK2
constructs were greatly overexpressed in NIH/3T3 cells with
respect to endogenous mRNAs (Fig. 1a). However, NRK1-E98A
and NRK2-D100A mutant proteins did not accumulate
appreciably, indicating that these mutant proteins might be
unstable (Fig. 1b). For this reason, we only used the NRK1-D36A
and NRK2-D35A mutants for further experiments. As predicted
by the low basal NRK1 and NRK2 expression in NIH/3T3 cells,
empty vector-transfected cells did not display marked differences
in NADþ levels in response to NR treatment (Fig. 1c).
Also, overexpression of active NRK1 or NRK2 had no effect
on basal intracellular NADþ content but was sufﬁcient
to convert NIH/3T3 from an NR-nonresponsive cell line to an
NR-responsive cell line with increases in NADþ of B4-fold
(Fig. 1c). The assay further indicated that NRK1-D36A and
NRK2-D35A mutants possess no kinase activity, as NR failed
to increase NADþ levels when these mutant forms were
expressed (Fig. 1c). Thus, these data establish that increasing
NRK activity by transient overexpression is sufﬁcient to boost
NR-driven NADþ synthesis, suggesting a rate-limiting role for
NRK1 and/or NRK2 in NR utilization.
To modulate NRK isozyme expression stably and at a lower
level of overexpression, we generated stable NIH/3T3 cell lines
that integrated single copies of the Nmrk1 (F3T3-NRK1) or
Nmrk2 (F3T3-NRK2) genes, encoding for Flag-tagged NRK1 and
NRK2 proteins, repectively. This strategy led to detectable
increases in NRK1 protein levels (Fig. 2a) that were achieved
despite a 500-fold reduction in mRNA levels with respect to
transient overexpression systems (Figs 1a and 2a). By western
blot, NRK1 was effectively overexpressed but NRK2 was difﬁcult
to detect, despite robust increases at the mRNA level (Fig. 2a).
Given the pronounced tissue-speciﬁc expression of the NRK2
protein in mouse (Supplementary Fig. 1a,b), we considered the
possibility that NRK2 requires muscle-speciﬁc factors for stability
and therefore focused our efforts on NRK1. NRK1 protein levels
in F3T3-NRK1 were comparable to the endogenous levels of
NRK1 in tissues with high NRK1 expression, such as liver and
kidney (Supplementary Fig. 1c). F3T3-NRK1 cells showed very
signiﬁcant dose-dependent increases in NADþ accumulation
when NR was added to standard, NAM-containing DMEM at
concentrations as low as 100 mM, reaching maximal levels
at B1mM concentrations (Fig. 2b). Of note, despite the modest
expression of NRK2 in F3T3-NRK2 cells, this construct drove
signiﬁcant increases in NR-induced NADþ synthesis (Fig. 2b).
We also generated a variant of the F3T3-NRK1 cell line in
which the catalytically inactive form of NRK1 was
expressed (F3T3-D36A) (Fig. 2a). As expected from transient
overexpression experiments, NR-induced NADþ synthesis was
fully blunted in F3T3-D36A cells compared with the large
increases observed in F3T3-NRK1 cells (Fig. 2d). We next
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evaluated the role of NRK1 in the utilization of other NADþ
precursors, such as NMN and NAM. If NMN has the capacity to
enter cells by diffusion or a specialized transporter, it would only
require one enzymatic step (NMNAT1-3) to generate NADþ
and, therefore, its ability to increase NADþ synthesis should be
independent of NRK1 (Fig. 2c). On the other hand, if NMN is
dephosphorylated prior to cell entry, then NMN should show
dependence on NRK expression to form intracellular NADþ .
Consistent with a requirement of NMN to be dephosphorylated
to NR extracellularly, NMN could only increase NADþ synthesis
in F3T3-NRK1 cells, and less potently than NR (Fig. 2e). In
contrast, NAM enhanced NADþ synthesis irrespective of NRK1
overexpression (Fig. 2f), illustrating that NRK1 is dispensable for
NAM action. Considering that neither NAMPT nor NMNAT
isozyme expression were reduced in our NRK1 transgenic F3T3
models (Supplementary Fig. 1d), these data indicate that
NRK1 expression mediates NMN-driven NADþ synthesis in
3T3 ﬁbroblasts. Importantly, NRK1 overexpression did not
affect the expression of NADases, such as CD38 and its
homolog CD157, or the CD73 nucleotidase, all of which have
been reported to inﬂuence NMN conversion to NR15,27
(Supplementary Fig. 1d).
Extracellular conversion of NMN to NR by hepatic cells. We
next aimed to study NR and NMN metabolism in cell models of
the greatest physiological relevance. For this reason, we ﬁrst
analysed NRK1 expression in mouse tissues. The Nmrk1 gene is
ubiquitously expressed at the mRNA level (Supplementary
Fig. 1a) and the liver, an organ mediating many of the
metabolic effects of NR19,23,28, displayed high NRK1 protein
levels (Fig. 3a). When we injected mice with 500mg kg 1 of
NR intraperitoneally, NR elevated NADþ levels in liver,
muscle, brown adipose tissue and brain within 60min (Fig. 3b).
Consistent with high level expression of NRK1 in liver, the
fold-change of increased NADþ was greater in liver than in
other tissues (Supplementary Fig. 2a). This result suggests the
possibility that tissues might have selective preferences for
different NADþ precursors to sustain NADþ levels2. To test
this hypothesis, we examined the sensitivity of different cell types
to NAMPT inhibition. Thus, we treated primary hepatocytes,
primary brown adipocytes and the muscle cell line
C2C12—representing liver, brown adipose tissue (BAT) and
muscle, respectively—with FK866, a NAMPT inhibitor. While,
after 30 h of treatment, FK866 treatment decreased intracellular
levels by more than 80% in differentiated brown adipocytes
and C2C12 myotubes, primary hepatocytes still retained B50%
of their endogenous NADþ levels (Supplementary Fig. 2b).
The higher sensitivity of brown adipocytes and myotubes to
FK866 could already be appreciated after only 6 h of treatment.
Altogether, these results suggest that different tissues have
characteristic rates of ﬂux through the NAM salvage pathway
and the NRK pathway, which bypasses NAMPT. Importantly,
FK866 did not alter the response of these cell lines to
NR or NMN, illustrating how these compounds are
metabolized into NADþ in a NAMPT-independent manner
(Supplementary Fig. 2c).
Based on the ability of liver to convert supplemented NR to
NADþ , we focused on liver-derived cell lines for further
mechanistic analysis. NR treatment led to signiﬁcant increases
in NADþ content in HepG2, Hepa1.6 and AML12 cells (Fig. 3c,d
and Supplementary Fig. 2d). Western blot analyses in Hepa1.6
and AML12 conﬁrmed a correlation between NRK1 levels and
the ability of NR to enhance NADþ synthesis (Supplementary
Fig. 2e). Consistent with a rate-limiting role of NRK1, Nmrk1
overexpression in AML12 or HepG2 cells was sufﬁcient to boost
the effect of NR on NADþ synthesis (Fig. 3c,d).
To more closely compare the effect of NR and NMN on the
intracellular NADþ metabolome in cells that endogenously
express NRK1, we utilized HepG2 cells to perform stable isotope
tracer analyses. For this purpose, we labelled the carboxamide
oxygen of NR and NMN with 18O and treated HepG2 cells
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cultured in serum- and NAM-free medium. As shown in Fig. 4a,
[18O]-NR treatment of HepG2 cells led to a rapid rise in the ratio
between heavy and endogenous NR, which was followed by
incorporation of heavy label into NMN, NADþ , and the product
of NADþ -consuming enzymes, NAM. This occurred in parallel
with a drop in [18O]-NR in the medium from 10 to 3 mM over the
course of 24 h (Fig. 4b). No labelled [18O]-NMN or [18O]-NAM
appeared during this time in the media of [18O]-NR-treated
HepG2 cells (Fig. 4b), indicating that NR is incorporated intact
and serves as a direct NADþ precursor. In contrast, when cells
were treated with [18O]-NMN, there was a rapid appearance of
extracellular [18O]-NR (Fig. 4d) and enrichment of intracellular
[18O]-NR (Fig. 4c). Whereas more than half of the [18O]-NR was
internalized into NADþ metabolites at the 7 h time point, 80% of
extracellular [18O]-NMN was present as extracellular [18O]-NR
at this time point. The slow release of NR from NMN
was accompanied intracellularly by a persistently high labelling
of NR at all time points. These data are exactly consistent with
extracellular NMN as a source of extracellular and intracellular
NR and are kinetically inconsistent with transport of intact NMN
through the plasma membrane.
NRK1 is essential for NR and NMN to increase NADþ . We
next aimed to determine if NRK1 is essential for NR and NMN
metabolism into NADþ in liver-derived cells. Given the low
transfection efﬁciency of HepG2 cells, we moved to AML12
hepatocytes, in which we could decrease Nmrk1 mRNA and
NRK1 protein levels by 60% using speciﬁc siRNAs (Fig. 5a). This
knockdown was not sufﬁcient to fully blunt NR-driven NADþ
synthesis (Fig. 5b). These data suggested that residual NRK1
protein after the knockdown could account for the remaining
NR-stimulated NADþ production. In line with this possibility,
NR effectively increased NADþ in Hepa1.6 cells, which have
signiﬁcantly lower NRK1 levels compared with AML12
(Supplementary Fig. 2d,e).
To circumvent this problem, we generated a mouse model
with a constitutive ablation of the Nmrk1 gene (NRK1KO).
Homozygous NRK1KO mice were born at expected Mendelian
ratios and displayed no gross abnormalities. No Nmrk1 mRNA or
protein could be detected in any tissue examined including liver,
kidney, brown adipose tissue or muscle, and no compensation of
NRK2 in NRK1KO tissues was observed (Supplementary
Fig. 3a,b). We then isolated primary hepatocytes from WT and
NRK1KO mice. Hepatocytes isolated from WT mice showed
comparable levels of NRK1 expression to that of endogenous liver
(Supplementary Fig. 2e), whereas the NRK1 protein was
undetectable in hepatocytes from NRK1KO mice (Fig. 5c). The
expression of other enzymes related to NADþ biosynthesis
(NAMPT and the NMNAT isozymes), NADþ consuming
enzymes (CD38, CD157 and PARP-1) or ecto-50-nucleotidases
(CD73) was comparable between genotypes (Fig. 5c,d). Strikingly,
NR and NMN increased NADþ levels in WT primary hepatocytes
but not in primary hepatocytes from NRK1KO mice (Fig. 5e). In
contrast, primary hepatocytes from NRK1KO mice increased
NADþ levels on NA or NAM treatment normally, indicating a
speciﬁc defect in NR utilization. Thus, NRK1 is required for the
utilization of exogenous NR and NMN in liver cells.
Inability of NRK1-deﬁcient hepatocytes to utilize NMN
further suggests that NMN enters the cell in the form of NR.
To further test this hypothesis, we blocked the possible
NMN to NR conversion in hepatocytes using high concentration
of cytidine monophosphate (CMP)16. Whereas CMP did
not affect NR action, it fully inhibited the increase in NADþ
on NMN supplementation, showing the necessity of NMN
dephosphorylation to NR by an enzyme that is competitively
inhibited by CMP (Fig. 6a).
To conduct the most stringent test of NMN utilization, we
made use of wild-type and NRK1KO hepatocytes, double-labelled
NADþ precursors, and a quantitative, targeted NADþ
metabolomic ﬂux experiment performed with LC-MS. NR and
NMN were each synthesized such that the NAM (13C) and
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the ribose (2H) moieties are labelled. Primary hepatocytes from
WT and NRK1KO mice were exposed to these compounds at
10 mM for 6 h and the extent of incorporation of double-labelled
NR and NMN into double-labelled intracellular NADþ
metabolites was determined. As shown in Fig. 6b, double-labelled
NR has a profound advantage in incorporation of double-labelled
NMN, NADþ and NADP with respect to double labelled NMN.
By the 6 h time point, 40–50% of cellular NMN and NADþ and
nearly 10% of cellular NADP incorporated both labels when
wild-type hepatocytes were exposed to double-labelled NR. If, as
previously reported9, primary hepatocytes incorporate an
intact NMN to form NADþ , then exposure to double labelled
NMN would have produced double-labelled intracellular
NMN and potentially a faster and/or more highly incorporated
population of intracellular metabolites. However, intracellular
double labelled NMN was not observed in the 6 h time course
nor were appreciable levels of any double-labelled NADþ
metabolite observed when wild-type hepatocytes were
exposed to double-labelled NMN (Fig. 6b). This would be
consistent with a slower and/or less potent action of NMN
due to the need for dephosphorylation into NR to drive NADþ
synthesis. As shown in Fig. 6c, the ability of hepatocytes
to convert double labelled NR to all double-labelled
NADþ metabolites is completely NRK1-dependent. This
experiment shows conclusively that NMN does not bypass
NRK1 and that liver cells depend on NRK1 to convert
extracellular NR to NADþ .
NRK1KO mice are deﬁcient in NR and NMN utilization in vivo.
Finally, to dissect the dependence of NADþ precursors on
NRK1 in the in vivo synthesis of hepatic NADþ , we delivered
500mgkg 1 NR, NMN, NAM or saline to wild-type and
NRK1KO mice by intraperitoneal injection. All precursors led to
large increases of NADþ levels in WT livers collected 1 h after
injection (Fig. 7a). NR increased liver NADþ content byB220%
in WT mice (Fig. 7a,b), whereas NAM and NMN increased
NADþ over basal levels to a lesser extent (B170%). While the
effects of NAM were similar in WT and NRK1KO mice, the
responses to both NR and NMN were signiﬁcantly blunted in
NRK1KO mice compared to WT controls (Fig. 7a,b). However,
about 60% of the NR and NMN effect on NADþ remained
in NRK1KO mice. To rule out the inﬂuence of nonspeciﬁc
conversions due to high doses of compounds used, we also
injected mice with lower doses of 50mgkg 1. At the lower
doses, NRK1 deﬁciency only partially blunted the increase in
hepatic NADþ production after NR and NMN injection
(Supplementary Fig. 3c).
In addition to liver, we evaluated kidney, BAT and skeletal
muscle NADþ levels after IP delivery of the different
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NADþ precursors. As in liver, the ability of NAM to trigger
NADþ synthesis was comparable between WT and NRK1KO
mice in all tissues analysed (Fig. 7c–h). In line with high
NRK1 expression in kidney (Fig. 3a and Supplementary Fig. 1a),
NR and NMN were very effective NADþ precursors in this
tissue, and their ability to enhance NADþ synthesis was blunted
byB70% in NRK1 deﬁcient mice (Fig. 7c,d). Opposite to kidney,
BAT has rather moderate NRK1 expression and relatively lower
increases in NADþ levels, but NR and NMN actions were also
largely blunted in NRK1 KO mice (Fig. 7e,f). These results
indicate that in liver, kidney and BAT, NR and NMN actions on
NADþ synthesis after IP delivery are largely, but not completely,
blunted by NRK1 deﬁciency. Muscle was the tissue with the
lowest response to NADþ precursors, which might explain why
we could not detect major differences between WT and NRK1KO
mice in their response to NR or NMN. Taking into account that
in muscle there is high expression of NRK2, we hypothesized that
NRK2 might be able to compensate for NRK1 deﬁciency. We
therefore intraperitoneally administered NAM, NR and NMN to
Nmrk1 and Nmrk2 double KO mice (NRK1/NRK2DKO).
However, WT mice and NRK1/NRK2DKO displayed comparable
increases in NADþ levels in skeletal muscle after intraperitoneal
NR and NMN administration (Supplementary Fig. 3d).
In yeast, an NRK-independent, NR salvage pathway is initiated
by the activities of Urh1, Pnp1, and, to a slight degree,
Meu1, which split NR into a ribosyl product and NAM26.
Because Pnp1 is the yeast homologue of mammalian purine
nucleoside phosphorylase29, we anticipated that NAM
produced by breakdown of intraperitoneal injected precursors
could be responsible for NRK1-independent synthesis of NADþ
in liver.
We therefore analysed NR, NMN and NAM levels in plasma
and livers obtained from these animals. Injection of NAM did not
signiﬁcantly alter hepatic NAM content, but led to comparable
increases in NAM plasma levels (B45-fold) in both WT and
NRK1KO mice (Fig. 8a,b, respectively). Strikingly, both NR
and NMN injection also led to signiﬁcant increases of NAM in
plasma, independent of genotype (Fig. 8b). This indicates that
both NR and NMN are partially converted to NAM upon
intraperitoneal injection, thereby accounting for the ability of
NRK1KO mice to increase NADþ content in liver upon NR
or NMN administration. To test whether the breakdown of NR
and NMN into NAM is due to chemical or enzymatic
degradation, we determined the stability of these compounds in
isolated murine plasma. NR incubation in murine plasma leads to
relatively quick degradation, with B10% of NR degraded after
10min and B66% degraded after 1 h (Fig. 8e), which is further
illustrated by gradual increase in NAM abundance in the samples
(Fig. 8g). On the contrary, NMN is stable in plasma and there is
no NAM increase in NMN samples up to 1 h incubation
(Fig. 8f,g). The results indicate the existence of plasma factor
that degrades NR into NAM. Moreover, it additionally hints that
the appearance of NAM in plasma of mice injected with NMN
may come after initial conversion of NMN into NR. Importantly,
NR is stably associated with protein fractions in milk25 with a
lifetime of weeks and may be circulated in a cell-associated form
in animals with a lifetime of hours. NR and NMN are both stable
when incubated in minimal essential medium (MEM) at 37 C up
to 6 h (Supplementary Fig. 4a,b). However, NR but not NMN
degradation with appearance of NAM could be observed when
supplementing media with 10% FBS (Supplementary Fig. 4a–c).
Therefore, the increases in NADþ observed in NRK1KO tissues
after NMN or NR administration likely derive from the
conversion of these precursors to NAM.
In our analyses, NMN levels were poorly detectable in mouse
plasma, at concentrations around the detection limit of our assays
(B20 nM). Though plasma NR levels were also at the limit of
detection, NR-injected NRK1KO mice displayed a signiﬁcant
increase in circulating NR levels compared with vehicle treatment
(Fig. 8d). Further, hepatic NR increased in NRK1KO mice after
administration of NR and modestly after NMN (Fig. 8c),
establishing that NR entry into the liver is unaffected in NRK1KO
mice but accumulates due to low NR phosphorylation. The data
conﬁrm that NRK1 is crucial for maximal NADþ elevation in
response to both NR and NMN.
Discussion
Supplementation with NR and NMN has recently been shown to
promote largely overlapping beneﬁts on metabolic health,
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mitochondrial and neurodegenerative disorders3. Although both
compounds lead to NADþ synthesis, speciﬁc analysis of their
bioavailability and metabolism remained to be elucidated.
Our work identiﬁes NRK1 as the central rate-limiting enzyme
for the utilization of both compounds and, consequently, for their
metabolic beneﬁts.
NRK1 and NRK2 were initially described as highly conserved
mammalian homologs of yeast Nrk1 with the ability to
convert NR to NMN in a newly identiﬁed pathway of eukaryotic
NADþ biosynthesis18. Despite similar enzymatic activities, these
enzymes display distinct tissue expression patterns. The baseline
expression of the Nmrk2 gene is highly restricted to muscle and
this enzyme proved to be unstable when ectopically expressed in
cultured ﬁbroblasts. This led us to focus on the more ubiquitously
expressed NRK1 isozyme. Here we show that although NRK1 is
dispensable for maintenance of basal NADþ levels in cells
cultured in standard NAM-containing media, it is rate-limiting
for cells to utilize NR and NMN as sources of NADþ . In sharp
contrast, NRK1 is dispensable for conversion of NAM and NA
into NADþ . In addition, our data from quantitative mass
spectrometry clearly show that in vitro NR supplementation does
not lead to NAM accumulation in the media at any point before
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NADþ synthesis. In vivo, however, intraperitoneal NR and NMN
administration quickly lead to increases in NAM. Our results
further demonstrate that while NR is spontaneously converted to
NAM in cell-free plasma, NMN is more resistant to this process
in vitro. This indicates that the comparable increases in NAM
levels observed after NMN administration likely derive
from NMN to NR dephosphorylation. The chronic effects of
NR or NMN on health, however, are unlikely to rely on their
transformation to NAM, for example, many of the beneﬁts of
NR and NMN are attributed to sirtuin activation, as both
compounds led to higher sirtuin activities from yeast to
mammals9,19–21,23,28,30. NAM, in contrast, is a well reported
and widely used sirtuin inhibitor31 and has been recently shown
to inhibit NADþ -consuming activities in vivo24. Similarly, both
NMN and NR protect against insulin resistance and axotomy-
induced axonal degeneration9,19,32, an effect that has not been
observed with NAM32,33.
While extracellular dephosphorylation of NMN into NR is
necessary for its utilization in yeast34, the means by which
NMN is utilized by mammalian cells remained controversial.
NMN was proposed to circulate at high abundance and serve
as a whole body NADþ precursor9,14. However, NMN has
proven challenging to detect in blood. Whereas NMN
concentration has been reported to reach around 50mM in
plasma14, our study and others13 have failed to detect comparable
levels of circulating NMN. These differences might be consequent
to the use of different methodologies to measure NMN.
For example, using one-dimensional HPLC-based methods,
NMN intracellular concentrations were reported to rise up to
B400–500 pmolmg 1 of white adipose and pancreatic
tissue 15min after intraperitoneal injection of 500mg kg 1 of
NMN, parallel to a peak level of NADþ in white adipose tissue
of B50 pmolmg 1 (ref. 9). However, by LC-tandem MS and
with the use of internal standards, the baseline concentrations
of hepatic NMN and NADþ were determined to be B2
and B1,000 pmolmg 1, respectively, rising to B10 and
B4,000 pmolmg 1, respectively, 6 h after oral gavage of
185mg kg 1 NR24. This is also consistent with recent reports
of NMN levels around 1.5 pmolmg 1 tissue in tumours and
B80 nM NMN in ascites ﬂuid17. These results highlight the
need to standardize NADþ -metabolomic measurements with
methods that are quantitative and multidimensional.
Irrespective of the circulating NMN concentration, our work
indicates that NMN dephosphorylation to NR constitutes a critical
step in order to act as an exogenous NADþ precursor. This is
sustained by several studies suggesting that the extracellular
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receptor CD73 could act as a potential NR-releasing enzyme15.
CD73 possesses pyrophosphatase and 50-ectonucleotidase activities
that enable the utilization of extracellular NADþ and NMN by
converting them to NR, which would then enter the cell for
NADþ synthesis15. In line with this, CD73 silencing blocks the
use of NMN as an extracellular NADþ precursor17. Our NRK1
gain- and loss-of-function models provide further evidence that
NMN is extracellularly dephosphorylated to NR for its utilization
as an NADþ precursor. If NMN were directly incorporated into
the cell, its conversion to NADþ would only require NMNAT and
not depend upon NRK1 activity. These data, together with our
data on CMP inhibition and kinetic studies using tracer
compounds, provide compelling evidence for the extracellular
conversion of NMN to NR for subsequent conversion to NADþ
through the NRK pathway. Though yeast cells express a dedicated
NR transporter35, most of the evidence suggests that mammalian
cells rely upon equilibrative nucleoside transporters (ENTs) to
import NR16,17. Inhibition of ENTs also largely prevented NR-
induced NADþ synthesis in our F3T3-NRK1 cells (Supplemen-
tary Fig. 5a). Accordingly, NMN was unable to generate NADþ
when ENTs where pharmacologically blocked16,17, indicating that
NMN extracellular dephosphorylation is not a side reaction
occurring concomitant with NMN direct transport but is the
exclusive pathway for utilization of extracellular NMN in NADþ
synthesis.
NRK isozymes are highly conserved through evolution, which
indicates a primordial need for NR as an NADþ precursor18. In
addition, the induction of NRK2 in response to cellular damage
or stress32 suggests the existence of a demand for circulating NR.
The natural source of oral NR, NAM and NA is largely the
NADþ in the food we eat as broken down by digestion and
the microbiome2,3. Interestingly, it was recently shown that
human cytosolic 50-nucleotidases can catalyse the conversion of
NMN into NR inside the cell and that at least some cells are able
to release nucleoside precursors of NADþ synthesis for other
cells36, which also suggests that NR is in circulation. Finally, the
presence of NR in bodily ﬂuids is also supported by the fact that
several bacteria affecting humans, such as Haemophilus inﬂuenza
and Streptococcus pneumoniae rely on exogenous NR to support
NADþ synthesis and life37,38. Future work will be required to
fully characterize circulating NADþ , NMN and NR, which may
be cell-associated. Nonetheless, the different efﬁcacy of NAM and
NR to boost NADþ synthesis and protect against metabolic
dysfunctions, indicate that NR and NAM are distinct vitamins
with non-identical tissue and cellular activities. This concept was
established by a recent study in which orally administered
equimolar NAM, NR and NA produced unique effects on hepatic
NADþ metabolism through distinct biosynthetic routes24.
This experiment, conducted in parallel with a human
clinical trial at the same effective dose of NR, showed that
NR produces the greatest rise in liver NADþ synthesis, followed
by NAM and NA24.
By establishing NRK1 as a rate-limiting and essential enzyme
for NR and NMN metabolism, we highlight NR and NMN as
convergent NR supplementation strategies. Further work will be
needed to optimize compositions or formulations that may be
preferentially targeted to particular organs to provide nutritional
and therapeutic beneﬁts.
Methods
Materials. All chemicals and reagents were purchased from Sigma-Aldrich
unless speciﬁed otherwise. NR Cl salt was synthesized and provided by Biosynth.
18O-labelled NR39 was synthesized from 18O-nicotinamide, prepared by hydrolysis
of cyanopyridine in 18O-water. 18O-labelled NMN was prepared from 18O-NR
by phosphorylation with NRK1 (ref. 18). 13C-nicotinamide was synthesized from
13C-nicotinic acid (purchased from Toronto Chemical Research) according to
Von Elverfeldt et al.40. Labelled D-ribofuranose 1,2-2H,3,5-tetraacetate (precursor
to Vorbru¨ggen glycosylation) was synthesized from D-[2-2H]-ribose (purchased
from Omicron Biochemicals) according to Begley et al.41 Double labelled 13C-2H
nicotinamide riboside was synthesized from 13C-nicotinamide and D-ribofuranose
1,2-2H,3,5-tetraacetate according to Vorbru¨ggen’s methodology described by Sobol
et al.42. 13C-2H nicotinamide mononucleotide was synthesized from double
labelled 13C-2H nicotinamide riboside according to procedures described by
Lee et al. and references therein43. Analytical methods and reports on labelled
and unlabelled NR and NMN are provided as Supplementary Methods and
Supplementary Fig. 6, respectively. NMN was puriﬁed by HPLC on a strong anion
exchange column with a 10–750mM gradient of KH2PO4 (pH 2.6). Isotopic purity
was assessed by LC-MS and concentration was assessed using an extinction
coefﬁcient (260 nm) of 4,200M 1 cm 1.
Plasmids. The coding regions of mouse Nmrk1 (NM_145497.2) and Nmrk2
(NM_027120.2) were ampliﬁed from Origene clones MC204637 and MC210962,
respectively, using KOD polymerase (Merck). The resulting PCR products was
digested with Bamh1-Not1 or Bgl2-Not1 and ligated into a Flag modiﬁed pCMV5
vector (AF239249.1), in which the Not1 site was in frame with the coding regions
to provide a C-terminal Flag tag on the proteins. In addition, forms with point
mutations (D36A and E98A in NRK1 as well as D35A and E100A in NRK2) were
created by PCR site-directed mutagenesis to generate enzymatically inactive
versions26. Sequences of all the clones were veriﬁed using the BigDye
Terminator 3.1 kit and 3500XL Genetic analyzer (Applied Biosystems).
Cell culture. All the cell lines used in the study come from ATCC and have been
tested for mycoplasma contamination using MycoProbe Mycoplasma Detection Kit
(R&D cat. CUL001B). NIH/3T3, Hepa1–6 and HepG2 cells were cultured in
DMEM supplemented with 10% FBS. AML12 cells were cultured in DMEM/F-12
medium supplemented with 10% FBS, 1x ITS-G and 100 nM dexamethasone.
C2C12 cells were cultured in DMEM supplemented with 20% FBS and
differentiated in DMEM supplemented with 2% horse serum for 4 days. For
overexpression experiments, cells were transfected with 4 mg of plasmid DNA using
Lipofectamine 3000 (Thermo Fisher) according to manufacturer’s instructions and
the treatments were performed 48 h post transfection. For knockdown experiments,
AML12 cells were transfected with 75 pmol siRNA (siRNA against mouse
Nmrk1 was obtained from Thermo Fischer) using Lipofectamine RNAiMAX
(Thermo Fisher) according to manufacturer’s instructions and the treatments were
performed 48 h post-transfection. NRK1 or NRK2 overexpressing stable cell lines
were generated from NIH/3T3 cells using FlpIn system (Invitrogen), in which an
expression vector containing the Nmrk1 or Nmrk2 gene was integrated into the
genome via Flp recombinase-mediated DNA recombination at the FRT site.
FlpIn cells were cultured in DMEM supplemented with 10% FBS and 100 mgml 1
Hygromycin B. For NADþ precursor response measurements, cells were
treated with 0.5mM NR, 0.5mM NMN, 0.5mM NA or 5mM NAM for 6 h unless
speciﬁed otherwise.
Nmrk1 KO mouse generation. NRK1-deﬁcient mouse models were generated on
a pure C57BL/6NTac background at Taconic Biosciences. Brieﬂy, exons 3 to 7 of
Nmrk1 gene were ﬂanked with loxP sites and ﬂoxed mice were crossed with
mice expressing the Cre recombinase under the general promoter of the
Gt(ROSA)26Sor gene (Cre deleter). The deletion of these exons was validated by
PCR (Supplementary Fig. 8), and resulted in the complete loss of the NRK1
protein. Mice carrying the whole body, including germ line, Nmrk1 deletion were
further bred to eliminate expression of the Cre recombinase. Age- and body
weight-matched males were randomly assigned into different treatments. Samples
from animal interventions were analysed and quantiﬁed in a blind manner.
Animal care. Unless otherwise speciﬁed, mice were kept in a standard
temperature- and humidity-controlled environment with a 12:12-h light:dark
cycle. Mice had nesting material and ad libitum access to water and a low-fat diet
(D12450J, from Research Diets Inc.). All animal experiments were carried
according to Swiss and EU ethical guidelines and approved by the local animal
experimentation committee under license 2770.
Primary hepatocyte isolation. Hepatocytes were isolated WT and NRK1KO mice
by continuous recirculating perfusion of the mouse liver in situ with collagenase
digestion44. Perfusion was performed in Krebs buffer (4.7mM KCl, 0.7mM KH2PO5,
10mM HEPES, 117mM NaCl, 24.6mM NaHCO3, 0.2% glucose) supplemented with
5mM CaCl2 and 0.5mgml 1 collagenase (Worthington, type IV) for 10min with
5mlmin 1 ﬂow. Cells were seeded in M199 containing 100Uml 1 penicillin G,
100mgml 1 streptomycin, 0.1% (w/v) BSA, 10% (v/v) FBS, 10 nM insulin, 200 nM
triiodothyronine and 100nM dexamethasone. Post attachment (4–5 h), cells were
cultured overnight in M199 supplemented with antibiotics and 100nM
dexamethasone and used for experiments the following morning.
Primary BAT cells. Primary brown adipocytes cells were obtained from the
interscapular BAT of WT mice. Immortalized brown pre-adipocytes were grown
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until 90% conﬂuence in ‘growth medium’ (DMEM supplemented with 10% FBS,
0.02 mM Insulin, and 1.5 nM 3,30 ,5 Triiodothyronine (T3)) and next differentiated
during 36 h with growth medium supplemented with 0.5 mM dexamethasone, 1 mM
rosiglitazone, 0.125 mM indomethacin and 0.5mM isobutylmethylxanthine. Then,
cells were cultivated in growth medium until day 6 of differentiation45.
Western blotting. Cells were lysed in 50mM Tris-Cl pH 7.5, 150mM NaCl, 5mM
EDTA, 1% NP40, 1mM Na butyrate with protease inhibitors. Proteins were
quantiﬁed using a BCA assay (Pierce). For western blotting, proteins were
separated by SDS– polyacrylamide gel electrophoresis and transferred onto
nitrocellulose membranes before incubation with primary antibodies against Flag
M2 F1804, a-tubulin T9026 (Sigma); NAMPT A300-372A (Bethyl); CD73 #13160,
GAPDH #2118 (Cell Signaling); CD38 sc-7049, CD157 sc-7115, PARP1 sc-1561
(SantaCruz); poly(ADP-ribose) ALX-210–890 (Enzo); or NRK1 and NRK2. NRK1
and NRK2 antibodies were puriﬁed by YenZym Antibodies from rabbits
immunized with CTRSEEDLFSQVYEDVKQELEKQNGL and CKSPEGLFHQV-
LEDIQNRLLNTS peptides, respectively. Primary antibodies were used in 1:5,000
dilution for GAPDH and a-tubulin and 1:1,000 dilution for others. Antibody
detection reactions were developed by enhanced chemiluminescence (Amersham).
All uncropped western blots are available in Supplementary Fig. 9.
RNA extraction and qPCR. Total mRNA from all studied tissues or cells was
extracted using TRIzol (Life Technologies) according to manufacturer’s
instructions. RNA concentrations were measured with Nanodrop 1000
(Thermo Scientiﬁc). Reverse transcription was performed using SuperScript II
(Life Technologies) with oligo dT plus random hexamer primers and RNAsine
(Roche) according to the manufacturer’s protocol. Quantiﬁcation of mRNA
expression was performed using SYBR Green real time PCR technology (Roche).
Reactions were performed in duplicate in a 384-well plate using the Light Cycler
(Roche). Gene expression was normalized with b2-microglobulin and cyclophillin as
housekeeping genes. Relative gene expression between genotypes was assessed using
the DDCt method. Primers used: Nmrk1 (50-CCCAACTGCAGCGTCATA
TC-30), Nmrk2 (50-GCCGTATGAGGAATGCAAGC-30), Nampt (50-AGTGGCCA
CAAATTCCAGAGA-30), Nmnat1 (50-TGGCTCTTTTAACCCCATCAC-30),
Nmnat3 (50-TCACCCGTCAATGACAGCTAT-30), b2-microglobulin (50-ATGGGA
AGCCGAACATACTG-30), cyclophillin (50-CAGGGGAGATGGCACAGGAG-30).
NADþ assay. NADþ was extracted from cells or tissues and measured by
EnzyChrom NAD/NADH Assay Kit (BioAssay Systems) performed according to
manufacturer’s instructions.
NADþ metabolome enrichment analysis using labelled compounds. NADþ
metabolite enrichment in HepG2 cells, primary hepatocytes and cultured media
was determined using LC-MS/MS46. Brieﬂy, cells were incubated in NAM-free,
serum-free DMEM for 24 h at which time cells were dosed with either labelled NR
or labelled NMN at 10 mM ﬁnal concentration. At 0, 0.5, 2, 4, 7 and 24 h, media
were collected and snap-frozen while cells were trypsinized, centrifuged, washed
with ice-cold PBS and snap-frozen in liquid nitrogen. All media and cells were
stored at  80 C before analysis. Media were diluted 1:1 with LC-MS grade water
containing internal standard (10 mM cytidine) and injected for analysis. Cell pellets
were washed in ice-chilled PBS, resuspended in 300ml of a 75% ethanol/25%
10mM HEPES, pH 7.1 solution that had been preheated to 80 C. Samples were
then shaken at 1,000 r.p.m. at 80 C for 3min. Soluble metabolites were recovered
after 10min centrifugation at 16 kg (ref. 46). A260 values of extracts were
determined using a Thermo Scientiﬁc 2000c Nanodrop. All cellular extracts were
diluted to an A260 value of 7, injected and analysed. Extracellular metabolites were
quantiﬁed by comparing the ratio of analyte area to the area of internal standard in
sample compared with a standard curve in water. Intracellular enrichment was
measured by dividing the 18O analyte areas by their 16O analyte isotopologues.
Enrichments were corrected for natural isotope abundance where necessary.
Further details on the synthesis of labelled compounds and multiple ion detection
spectra of unlabelled and double labelled NR and NMN are described in
Supplementary Figs 6 and 7.
Analysis of NR, NAM and NMN by LC-QqQ MS. Fifty microlitres of freshly
thawed plasma and 2mg of lyophilized liver were mixed with 150 and 200 ml,
respectively, of 100mM ammonium acetate water:acetonitrile 15:85 (v/v). Plasma
extract was vortexed vigorously for 20 s, while liver extract was homogenized with
0.5mm stainless steel beads using a Bullet Blender (Next Advance). The resulting
plasma and liver extracts were incubated on ice for 1 h for protein precipitation and
centrifuged at 15,000 r.p.m. at 4 C for 10min. The resulting supernatant was
transferred to an LC-MS vial. Plasma extract supernatant was diluted 1:10 in
100mM ammonium acetate water:acetonitrile 15:85 (v/v), while liver extract
supernatant was directly analysed by LC-MS. To avoid degradation effects analyses
were done within 12 h.
NAM, NR and NMN metabolites were determined in a 1290 UHPLC coupled
to a triple quadrupole 6490 iFunnel QqQ/MS (Agilent Technologies), using an
Acquity UPLC BEH HILIC column of 1.7 mm and 2.1 100mm (Waters). Injected
sample volume was 1 ml at a ﬂow rate of 0.5mlmin 1 using 100mM ammonium
acetate (solvent A) and acetonitrile (solvent B) as mobile phases with an elution
gradient of 0–1min 85% B, 2min 20% B, 2–3min 20% B isocratic, 3–3.5min 15%
B, 3.5–7min 15% B isocratic and 8min 85% B. ESI conditions were 150 C and
12 lmin 1 for drying gas temperature and ﬂow, 20 p.s.i. of nebulizer gas pressure,
350 C and 12 lm 1 for sheath gas temperature and pressure, 3,500V of capillary
voltage and 500V of nozzle voltage. The QqQ was operated in multiple reaction
monitoring mode and positive polarity, applying a fragmentor voltage of 380V
and a cell accelerator voltage of 3V. Multiple reaction monitoring transitions were:
NR (255-123, 106), NAM (123-78, 80, 53), NMN (335-123, 97, 80).
Quality control (QC) samples consisting of pooled plasma or liver extracts, were
alternatively inserted along the run sequence. Furthermore, experimental samples
were randomized to reduce systematic error associated with instrumental drift.
Relative quantiﬁcation of compounds was done by comparison of the integrated
areas (Supplementary Table 1).
Statistical analyses. Statistical analyses were performed with GraphPad Prism
version 5.02 for Windows (La Jolla, CA, USA). In vitro analysis were performed in
duplicates in three separate experiments. On the basis of an a priori power analysis,
the studies were powered to allow signiﬁcant detection of differences reaching
medium size (20–30%) with 480% power in case the number of estimated false
positive is set to 5%. Differences between two groups were analysed using a Stu-
dent’s two-tailed t-test. One-way ANOVA analysis with Bonferroni post-test was
used when comparing more groups. Group variances were similar in all cases. A P
value o0.05 was considered signiﬁcant. Data are expressed as means±s.e.m.
Data availability. The data that support the ﬁndings of this study are available
from the corresponding authors upon request.
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